Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Walmart

Richard Pzena (Trades, Portfolio), leader of Pzena Investment Management LLC, sold shares of the following stocks during the fourth quarter.

Richard Pzena Trims Walmart, Merck Positions

Another win for the seeming unstoppable drug -- this time in metastatic triple-negative breast cancer.

Merck's Keytruda Helps Treat an Aggressive Form of Breast Cancer

Seagen

Seattle Genetics posted eye-popping data from a study of patients given a combination of Padcev and Keytruda.

Seattle Genetics, Astellas, and Merck Hit a Bladder Cancer Bullseye

Merck stock fell on news it will spin off slow-growth areas to focus on Keytruda, its anti-cancer immunotherapy blockbuster.
The post Merck’s Spinoff Plans Place a Big Bet on Cancer-Fighting Keytruda appeared first on InvestorPlace.

Merck’s Spinoff Plans Place a Big Bet on Cancer-Fighting Keytruda

AbbVie

Agile Therapeutics

Amarin Corporation Plc

Esperion Therapeutics

Eli Lilly

From a niche contraceptive to the world's top cancer treatment, the FDA has a number of interesting drugs its reviewing this month.

4 Dates Biotech Investors Should Circle in February

It wasn't a big hit with investors on Wednesday.

Is Merck's Decision to Slim Down a Buying Opportunity?

Merck stock advanced 19% in all of 2019. Meanwhile shares of other pharmaceutical companies grabbed smaller, single-digit percentage gains.

Merck Stock Is Forming A Flat Base — But Is It Time To Take On Shares?

Merck & Co. Inc. (NYSE:MRK) was a drag on the Dow Jones Industrial Average on Feb.

Merck Shares Drop After Spinoff Announced

Merck (MRK) earnings for the healthcare company's fourth quarter of 2019 have MRK stock down Wednesday on major spin-off news.
The post Merck Earnings: MRK Stock Moves 4% Lower on Spin-Off News appeared first on InvestorPlace.

Merck Earnings: MRK Stock Moves 4% Lower on Spin-Off News

Merck & Co., Inc. (MRK) CEO Ken Frazier on Q4 2019 Results - Earnings Call Transcript

The pharma giant will form a new publicly traded company out of its women's health and biosimilars businesses, and its legacy brands.

Merck Announces a Big Planned Spinoff

In recent years, investors frequently have run into issues being invested in major pharmaceutical companies.

Merck’s Spin-Off May Create Operational Risks for the Year Ahead

Pharma giant Merck & Co., Inc. (NYSE: MRK) announced Wednesdaythat it plans to splinter into two companies in a bid to pursue aggressive growth.

Merck To Spin Off Slow-Growing Women's Health, Legacy, Biosimilars Businesses: What You Need To Know

The drugmaker had some good news, some bad news, and some big news.

The 4 Most Important Things to Know About Merck's Q4 Earnings Results

Merck & Co. Inc. (NYSE: MRK) reported its fourth-quarter financial results before the markets opened on Wednesday.

Is Merck Stuck in the Slow Lane?

Merck (MRK) beats estimates for earnings but misses the same for sales in fourth-quarter 2019. The company plans to spin off Women Health drugs/biosimilars into new company.

Merck (MRK) Beats on Q4 Earnings, Plans Women Health Spin Off

Merck & Co. Inc.'s stock MRK, +1.17% sank 4.3% in premarket trading Wednesday, and was the only Dow Jones Industrial Average DJIA, +1.44% component losing ground, after the health care and drugs company reported fourth-quarter results, and said it was spinning off businesses.

Merck's stock is the only Dow member losing ground, after earnings and spinoff news

Merck & Co (NYSE: MRK) reported quarterly earnings of $1.16 per share on Wednesday, which beat the analyst consensus estimate of $1.15 by 0.87%.

Merck Reports Mixed Q4 Earnings

Merck & Co. Inc. MRK, +1.17% announced Wednesday that it was spinning off its Women's Health, Trusted Legacy Brands and Biosimilar Products businesses into a separate publicly traded company, while also reporting a fourth-quarter profit that topped expectations while sales came up a bit short.

Merck announces spinoffs, reports profit beat but sales miss; stock falls

Merck topped Q4 earnings views but sales missed. The Dow Jones drug giant will spin off its women's health, biosimilars and legacy products into a new company.

Merck Earnings Mixed; Drug Giant To Spin Off Women's Health, Biosimilars

Merck on Wednesday announced plans to spin off nearly 90 products into a new publicly traded company.

Merck to spin-off women's health, biosimilar businesses

Merck's major moneymaking drug, Keytruda, could unseat AbbVie's Humira as the best-selling drug. But an analyst said Tuesday the blockbuster cancer treatment will face competition in 2020.

Merck's Keytruda: How Long Can It Fend Off Cancer-Treatment Rivals?

Merck (MRK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.

Should You Buy Merck (MRK) Ahead of Earnings?

The FDA accepts Merck's (MRK) sNDA for antibacterial injection Recarbrio and grants priority review.

Merck's Recarbrio Gets FDA Priority Review for New Indication

In this uplifting and fascinating conversation, Ken Frazier, the highly successful CEO of pharmaceutical giant Merck, talks about a company having a soul and other interesting topics, including how he rose up from a very humble background.

News for Merck Stock (MRK)